Author

Donald G Phinney

Professor, Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for - Cited by 30,410 - Stem cells - Cell therapy - Cancer Biology - Lead Discovery

Biography

Donald G. Phinney is an alumnus of the University of Vermont and received his Ph.D. in Biochemistry from Temple University School of Medicine in 1990. He is currently a Professor in the Department of Molecular Medicine at the Scripps Research Institute in Jupiter, Florida. His lab combines basic and translational research with drug discovery to develop innovative and efficacious cell-based and RNA-targeting therapies for treating osteoporosis and cancer, and identify novel metrics to predict the potency of MSC-based therapies for different disease indications.
Title
Cited by
Year
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the …
C Théry, KW Witwer, E Aikawa, MJ Alcaraz, JD Anderson, ...Journal of extracellular vesicles 7 (1), 1535750, 2018201
6675
2018
Concise review: MSC-derived exosomes for cell-free therapy
DG Phinney, MF PittengerStem cells 35 (4), 851-858, 2017201
1281
2017
Mesenchymal stem cell perspective: cell biology to clinical progress
MF Pittenger, DE Discher, BM Péault, DG Phinney, JM Hare, AI CaplanNPJ Regenerative medicine 4 (1), 22, 2019201
1084
2019
Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature
S Viswanathan, Y Shi, J Galipeau, M Krampera, K Leblanc, I Martin, ...Cytotherapy 21 (10), 1019-1024, 2019201
471
2019
Small molecule inhibition of microRNA-210 reprograms an oncogenic hypoxic circuit
MG Costales, CL Haga, SP Velagapudi, JL Childs-Disney, DG Phinney, ...Journal of the American Chemical Society 139 (9), 3446-3455, 2017201
151
2017
Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019; 4: 22
MF Pittenger, DE Discher, BM Péault, DG Phinney, JM Hare, AI CaplanPubMed PubMed Central Article CAS, 2019201
73
2019
International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and …
V Börger, DJ Weiss, JD Anderson, FE Borràs, B Bussolati, DRF Carter, ...Cytotherapy 22 (9), 482-485, 2020202
72
2020
Mesenchymal stem cell‐derived extracellular vesicles reduce senescence and extend health span in mouse models of aging
A Dorronsoro, FE Santiago, D Grassi, T Zhang, RC Lai, SJ McGowan, ...Aging cell 20 (4), e13337, 2021202
51
2021
Manufacturing mesenchymal stromal cells for clinical applications: A survey of Good Manufacturing Practices at US academic centers
DG Phinney, J GalipeauCytotherapy 21 (7), 782-792, 2019201
47
2019
Improving mesenchymal stem/stromal cell potency and survival: Proceedings from the International Society of Cell Therapy (ISCT) MSC preconference held in May 2018, Palais des …
JA Nolta, J Galipeau, DG PhinneyCytotherapy 22 (3), 123-126, 2020202
43
2020
Basal p53 expression is indispensable for mesenchymal stem cell integrity
SV Boregowda, V Krishnappa, J Strivelli, CL Haga, CN Booker, ...Cell Death & Differentiation 25 (4), 679-692, 2018201
39
2018
Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition
J Galipeau, M Krampera, K Leblanc, JA Nolta, DG Phinney, Y Shi, K Tarte, ...Cytotherapy 23 (5), 368-372, 2021202
38
2021
Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential
M Khoury, PRM Rocco, DG Phinney, M Krampera, I Martin, ...Cytotherapy 22 (11), 602-605, 2020202
37
2020
Mesenchymal stem cells: the moniker fits the science
SV Boregowda, CN Booker, DG PhinneyStem Cells 36 (1), 7-10, 2018201
34
2018
ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19
V Börger, DJ Weiss, JD Anderson, FE Borràs, B Bussolati, DRF Carter, ...Cytotherapy, 2020202
21
2020
Quantifiable metrics for predicting MSC therapeutic efficacy
SV Boregowda, DG PhinneyJournal of stem cell research & therapy 6 (11), 2016201
21
2016
Mesenchymal Stem Cell (MSC)–Derived Extracellular Vesicles Protect from Neonatal Stroke by Interacting with Microglial Cells
P Pathipati, M Lecuyer, J Faustino, J Strivelli, DG Phinney, ZS VexlerNeurotherapeutics 18, 1939-1952, 212
20
2021
Consensus International Council for Commonality in Blood Banking Automation–International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for …
S Viswanathan, R Ciccocioppo, J Galipeau, M Krampera, K Le Blanc, ...Cytotherapy 23 (12), 1060-1063, 2021202
15
2021
IP6K1 reduces mesenchymal stem/stromal cell fitness and potentiates high fat diet-induced skeletal involution
SV Boregowda, S Ghoshal, CN Booker, V Krishnappa, A Chakraborty, ...Stem Cells 35 (8), 1973-1983, 2017201
15
2017
Rapid generation of miRNA inhibitor leads by bioinformatics and efficient high-throughput screening methods
CL Haga, SP Velagapudi, JL Childs-Disney, J Strivelli, MD Disney, ...Drug Target miRNA: Methods and Protocols, 179-198, 2017201
13
2017

Referred From: https://scholar.google.com/citations?user=Ixhn-sQAAAAJ&hl=en

Cited by
Citations 30410
h-index 51
i10-index 89
Recommended Journals
Open Access Journals